Darwin Discovery Limited

Ucb Pharma, S.a.

Kabushiki Kaisha Toshiba

Genentech, Inc.

Glaxosmithkline Intellectual Property Development Limited

Bnos Electronics Limited

F. Hoffmann-la Roche Ag

Almirall, S.a.

Genkyotex Suisse Sa

Jazz Pharmaceuticals Research UK Limited

Andrew Sharpe

Alan Findlay Haughan

Hazel Joan Dyke

Verity Margaret Sabin

Christopher Lowe

Alastair James Hodges

Mizio Matteucci

Andrew James Shields

Andrew Douglas Baxter

Xiaojing Wang

Minghua Sun

Roland W Bürli

George Martin Buckley

Daniel Rees Allen

Richard John Davenport

John Gary Montana

Gilles Raphy

Duncan Robert Hannah

Marianna Dilani Richard

Andrew Pate Owens

Zhiliang Yuan

Julie Nicole Hamblin

Wesley Peter Blackaby

David Alan Owen

Julien Alistair Brown

Vipulkumar Kantibhai Patel

Kevin James Doyle

Robert John Watson

Mark Stuart Chambers

Anthony William James Cooper

Vickie H Tsui

James Dynes

Niall Andrew Anderson

Jason Burch

Graham George Adam Inglis

Kenneth David Down

Elizabeth Anne Saville-Stones

Sebastien Andre Campos

Hannah Jayne Kendall

William Ross Pitt

Gemma Victoria White

Peter T Dearman

Simon Peace

Stephen Robert Mack

Nicholas Paul Barton

Christopher James Lock

Duncan Batty

Zakaria Moktadir

Jonathan David MacDonald

Armelle Le Gall

Natasha Kinsella

Edward Paul Cannons

Kevin Bowden

Damon Andrew Cookman

Howard Alfred Buckenham

Laura Jane Tait

Graham John Warrellow

Rikki Peter Alexander

Daniel Christopher Brookings

Peter J Machin

Stephen Brand

Silvia Fonquerna Pou

Stuart Bailey

Andrew James Ratcliffe

Karen Ann Runcie

David John Nash

Isabelle Anne Lemasson

Louise Picken

James Duffy

Alastair Rae

James Osborne

Catherine Louise Picken

Michael Daniel Goldsmith

Vivienne Allen

John M Ellard

Roland Burli

Sophie Caroline Williams

John Richard Davenport

Roland BÜRLI

Antoine Millet

Karen Ka-Yen Tse

Alan James Silcock

A photon detection device and method of fabricating a photon detection device are provided. The photon detection device comprises a first input terminal for receiving a DC input voltage, a second input terminal for receiving an AC input voltage and a bias tee connected to the first and second input terminals and configured to combine the AC and DC input voltages to form a combined voltage on an output of the bias tee. A first single photon detector is connected to the output of the bias tee and configured to receive the combined voltage from the bias tee, register a detection signal based on only a single photon being incident on the first single photon detector and output the detection signal indicative of the detected photon. A first output terminal is connected to an output of the first single photon detector for outputting the detection signal. The photon detection device is formed in a single integrated circuit.

On-chip integration of MMIC and single photon detectors

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Chemical compounds

The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives. 

Amino-substituted heterocyclic derivatives as sodium channel inhibitors

The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Amido thiadiazole derivatives as NADPH oxidase inhibitors

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Ris a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Triazine derivatives as kinase inhibitors

A communication system comprising an emitter of weak light pulses, a detector which is capable of detecting single photons, and a source of a clock signal, wherein said emitter and detector are synchronized using said clock signal, the system further comprising a frequency divider for said clock signal to produce a reduced frequency clock signal and a clock regenerator for regenerating the original clock signal from the reduced frequency clock signal, the system further comprising a communication channel configured to communicate the clock signal between the emitter and detector, the clock signal being reduced before sending through said channel and reconstructed after it has exited said channel.

Communication system and method

A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Quinoline derivatives as kinase inhibitors

A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Fused pyridine and pyrazine derivatives as kinase inhibitors

Growing community of inventors

Saffron Walden, United Kingdom

Andrew Sharpe